Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...

Primary Cells vs. Cell Lines: Cloud-Clone Corp. Empowers Researchers to Choose the Optimal Path for Discovery

The Trade-off Between Physiological Authenticity and Experimental Convenience: Navigating the Cellular Foundation of ...

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based ...
Cancer Therapy Advisor

Tislelizumab Plus Chemo Provides Sustained Survival Benefit in Metastatic Nasopharyngeal Cancer

The combination of tislelizumab and chemotherapy produced sustained and clinically meaningful survival benefits with manageable toxicity among patients ...
Targeted Oncology

Carfilzomib Restores BCMA Expression After BCMA CAR T in R/R Myeloma

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Researchers repurpose existing lung cancer drug to fight ovarian tumors

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity decreases, scans show improvement, and patient lifespans are prolonged for some ...

Allarity Therapeutics, Inc.: Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured ...
Frontiers

Unraveling Breast Cancer Complexity: Insights from Single-Cell Sequencing and Spatial Transcriptomics

Breast cancer remains one of the most prevalent and life-threatening forms of cancer, impacting millions worldwide. This malignancy's heterogeneity and complexity have long posed significant ...
Euractiv

Irish American team reveal breakthrough for treatment-resistant prostate cancer

Irish and American researchers have identified a potential new way to counter treatment‑resistant prostate cancer by ...

A landmark 'evolutionary double-bind' strategy to overcome treatment resistance in prostate cancer

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...
Irish Medical Times

‘Evolutionary double-bind’ could overcome treatment resistance in prostate cancer – research

Study is the first to directly quantify and validate a method of exploiting the way cancers evolve, both in the lab and through mathematical modelling ...

Allarity Therapeutics, Inc.: Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung CancerTrial is fully funded by the U.S. Department of Veterans Affairs and is open for enrol ...